[1] Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome[J]. J Neural Transm (Vienna), 2013, 120:1579-1589.
[2] Rajakaruna GK, Italiano CM, John M, Nolan D. Chorea associated with persistent low-level viremia in a patient living with HIV:a case report[J]. J Virus Erad, 2020, 6:27-29.
[3] Baizabal-Carvallo JF, Jankovic J. Autoimmune and paraneoplastic movement disorders:an update[J]. J Neurol Sci, 2018, 385:175-184.
[4] Honnorat J, Joubert B. Movement disorders in autoimmune encephalitis and paraneoplastic neurological syndromes[J]. Rev Neurol (Paris), 2018, 174:597-607.
[5] Nissen MS, Blaabjerg M. Anti-IgLON5 disease:a case with 11-year clinical course and review of the literature[J]. Front Neurol, 2019, 10:1056.
[6] van Sonderen A, Schreurs MW, Wirtz PW, Sillevis Smitt PA, Titulaer MJ. From VGKC to LGI1 and Caspr2 encephalitis:the evolution of a disease entity over time[J]. Autoimmun Rev, 2016, 15:970-974.
[7] Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias:practical guidelines and therapeutic challenges[J]. Curr Neuropharmacol, 2019, 17:33-58.
[8] Debes JD, Lagarde SM, Hulsenboom E, SillevisSmitt PA, ten Kate FJ, Sulter GA, van Lanschot JJ. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction[J]. Dig Surg, 2007, 24:395-397.
[9] Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, Graus F, Antoine JC. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies[J]. J Neurol Neurosurg Psychiatry, 2009, 80:412-416.
[10] McKasson M, Clardy SL, Clawson SA, Hill KE, Wood B, Carlson N, Bromberg M, Greenlee JE. Voltage-gated calcium channel autoimmune cerebellar degeneration:case and study of cytotoxicity[J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3:e222.
[11] Rigamonti A, Lauria G, Stanzani L, Mantero V, Andreetta F, Salmaggi A. Non-paraneoplastic voltage-gated calcium channels antibody-mediated cerebellar ataxia responsive to IVIG treatment[J]. J Neurol Sci, 2014, 336:169-170.
[12] Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2:paraneoplastic accompaniments[J]. Ann Neurol, 2003, 53:580-587.
[13] Gungor S, Kilic B, Arslan M, Ozgen U, Dalmau J. Erratum to:Hodgkin's lymphoma associated with paraneoplastic cerebellar degeneration in children. A case report and review of the literature[J]. Childs Nerv Syst, 2017, 33:1025.
[14] Lopez-Chiriboga AS, Komorowski L, Kümpfel T, Probst C, Hinson SR, Pittock SJ, McKeon A. Metabotropic glutamate receptor type 1 autoimmunity:clinical features and treatment outcomes[J]. Neurology, 2016, 86:1009-1013.
[15] Jarius S, Wildemann B. ‘Medusa-head ataxia’:the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1:anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP Ⅷ[J]. J Neuroinflammation, 2015, 12:166.
[16] Jarius S, Wildemann B. ‘Medusa head ataxia’:the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2:anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC[J]. J Neuroinflammation, 2015, 12:167.
[17] Jarius S, Wildemann B. ‘Medusa head ataxia’:the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3:anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook[J]. J Neuroinflammation, 2015, 12:168.
[18] Ariño H, Gresa-Arribas N, Blanco Y, Martínez-Hernández E, Sabater L, Petit-Pedrol M, Rouco I, Bataller L, Dalmau JO, Saiz A, Graus F. Cerebellar ataxia and glutamic acid decarboxylase antibodies:immunologic profile and long-term effect of immunotherapy[J]. JAMA Neurol, 2014, 71:1009-1016.
[19] Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, Ramió-Torrentà L, Graus F. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies:diagnostic clues for this association[J]. Brain, 2008, 131:2553-2563.
[20] Nakamura Y, Nakajima H, Hosokawa T, Yamane K, Ishida S, Kimura F. Acute cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies mimicking miller fisher syndrome[J]. Intern Med, 2018, 57:269-271.
[21] Hadjivassiliou M. Advances in therapies of cerebellar disorders:immune-mediated ataxias[J]. CNS Neurol Disord Drug Targets, 2019, 18:423-431.
[22] Dai X, Kuang L, Feng L, Yi X, Tang W, Liao Q, Long X, Wang J, Li J, Yang H, Xiao B, Li G, Chen S. Anti-dopamine receptor 2 antibody-positive encephalitis in adolescent[J]. Front Neurol, 2020, 11:471.
[23] Ramanathan S, Mohammad SS, Brilot F, Dale RC. Autoimmune encephalitis:recent updates and emerging challenges[J]. J Clin Neurosci, 2014, 21:722-730.
[24] Li Z, Cui T, Shi W, Wang Q. Clinical analysis of leucine-rich glioma inactivated-1 protein antibody associated with limbic encephalitis onset with seizures[J]. Medicine (Baltimore), 2016, 95:e4244.
[25] Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, Psimaras D, Habert MO, Baulac M, Delattre JY, Honnorat J; Collaborators. Motor cortex and hippocampus are the two main cortical targets in LGI1 antibody encephalitis[J]. Brain, 2016, 139:1079-1093.
[26] Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ, Boeve BF, Lowe V, Ahlskog JE, Shin C, Boes CJ, Crum BA, Laughlin RS, Pittock SJ. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2:e161.
[27] Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart J, Erro ME, Abraira L, Moris G, Monros-Giménez L, Corral-Corral Í, Montejo C, Toledo M, Bataller L, Secondi G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Graus F, Dalmau J; Spanish Herpes Simplex Encephalitis Study Group. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis:a prospective observational study and retrospective analysis[J]. Lancet Neurol, 2018, 17:760-772.
[28] Cavaliere E, Nosadini M, Pelizza MF, Ventura G, Toldo I, Sartori S. Anti-NMDAR encephalitis preceded by non-herpetic central nervous system infection:systematic literature review and first case of tick-borne encephalitis triggering anti-NMDAR encephalitis[J]. J Neuroimmunol, 2019, 332:1-7.
[29] Nosadini M, Mohammad SS, Corazza F, Ruga EM, Kothur K, Perilongo G, Frigo AC, Toldo I, Dale RC, Sartori S. Herpes simplex virus-induced anti-N-methyl-D-aspartate receptor encephalitis:a systematic literature review with analysis of 43 cases[J]. Dev Med Child Neurol, 2017, 59:796-805.
[30] Adams C, McKeon A, Silber MH, Kumar R. Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma[J]. Arch Neurol, 2011, 68:521-524.
[31] Ortega SG, Sola-Valls N, Escudero D, Saiz A, Graus F. Anti-Ma1 and anti-Ma2-associated paraneoplastic neurological syndromes[J]. Neurologia, 2018, 33:18-27.
[32] Mandel-Brehm C, Dubey D, Kryzer TJ, O'Donovan BD, Tran B, Vazquez SE, Sample HA, Zorn KC, Khan LM, Bledsoe IO, McKeon A, Pleasure SJ, Lennon VA, DeRisi JL, Wilson MR, Pittock SJ. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis[J]. N Engl J Med, 2019, 381:47-54.
[33] Kurtis MM, Toledano R, García-Morales I, Gil-Nagel A. Immunomodulated parkinsonism as a presenting symptom of LGI1 antibody encephalitis[J]. Parkinsonism Relat Disord, 2015, 21:1286-1287.
[34] Kannoth S, Nambiar V, Gopinath S, Anandakuttan A, Mathai A, Rajan PK. Expanding spectrum of contactin-associated protein 2(CASPR2) autoimmunity-syndrome of parkinsonism and ataxia[J]. Neurol Sci, 2018, 39:455-460.
[35] Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, Lennon VA. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction[J]. Mayo Clin Proc, 2006, 81:1207-1214.
[36] Tse W, Cersosimo MG, Gracies JM, Morgello S, Olanow CW, Koller W. Movement disorders and AIDS:a review[J]. Parkinsonism Relat Disord, 2004, 10:323-334.
[37] Hersh BP, Rajendran PR, Battinelli D. Parkinsonism as the presenting manifestation of HIV infection:improvement on HAART[J]. Neurology, 2001, 56:278-279.
[38] El-Abassi R, Soliman MY, Villemarette-Pittman N, England JD. SPS:understanding the complexity[J]. J Neurol Sci, 2019, 404:137-149.
[39] McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, Pittock SJ. Stiff-man syndrome and variants:clinical course, treatments, and outcomes[J]. Arch Neurol, 2012, 69:230-238.
[40] McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, Pittock SJ, Lennon VA, Dalmau J. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype[J]. JAMA Neurol, 2013, 70:44-50.
[41] Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Appendino JP, Lucchinetti CF, Matsumoto JY, Pittock SJ, Sandroni P, Tippmann-Peikert M, Wirrell EC, McKeon A. DPPX potassium channel antibody:frequency, clinical accompaniments, and outcomes in 20 patients[J]. Neurology, 2014, 83:1797-1803.
[42] Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies:distinctive features of a rare disease[J]. Neurology, 2008, 71:1955-1958.
[43] Nguyen-Huu BK, Urban PP, Schreckenberger M, Dieterich M, Werhahn KJ. Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer[J]. Mov Disord, 2006, 21:1285-1287.
[44] Butler MH, Hayashi A, Ohkoshi N, Villmann C, Becker CM, Feng G, De Camilli P, Solimena M. Autoimmunity to gephyrin in Stiff-man syndrome[J]. Neuron, 2000, 26:307-312.
[45] Montojo MT, Petit-Pedrol M, Graus F, Dalmau J. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex[J]. Neurologia, 2015, 30:295-301.
[46] Sunwoo JS, Lee ST, Byun JI, Moon J, Shin JW, Jeong DE, Lee GH, Jeong SH, Shin YW, Jung KH, Lee DY, Jeon D, Jung KY, Kim M, Lee SK, Chu K. Clinical manifestations of patients with CASPR2 antibodies[J]. J Neuroimmunol, 2015, 281:17-22.
[47] Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, Zuliani L, Watanabe O, Lang B, Buckley C, Vincent A. Morvan syndrome:clinical and serological observations in 29 cases[J]. Ann Neurol, 2012, 72:241-255.
[48] Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome[J]. J Pediatr Oncol Nurs, 2005, 22:8-19.
[49] Oh SY, Kim JS, Dieterich M. Update on opsoclonus-myoclonus syndrome in adults[J]. J Neurol, 2019, 266:1541-1548.
[50] Armangué T, Sabater L, Torres-Vega E, Martínez-Hernández E, Ariño H, Petit-Pedrol M, Planagumà J, Bataller L, Dalmau J, Graus F. Clinical and immunological features of Opsoclonus-Myoclonus syndrome in the era of neuronal cell surface antibodies[J]. JAMA Neurol, 2016, 73:417-424.
[51] Hu W, Xin Y, He Z, Zhao Y. Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy:a systematic review and Meta-analysis[J]. Brain Behav, 2018, 8:e01115.
[52] Hara M, Ariño H, Petit-Pedrol M, Sabater L, Titulaer MJ, Martinez-Hernandez E, Schreurs MW, Rosenfeld MR, Graus F, Dalmau J. DPPX antibody-associated encephalitis:main syndrome and antibody effects[J]. Neurology, 2017, 88:1340-1348.
[53] Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy[J]. Br J Haematol, 2018, 183:364-374.
[54] Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia[J]. Cancer Discov, 2018, 8:958-971.
[55] Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15:47-62.
[56] Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, G öppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy[J]. Eur J Cancer, 2016, 60:210-225.
[57] Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1(PD-1) antibodies[J]. JAMA Neurol, 2017, 74:1216-1222.
[58] Walker MD, Zylberberg HM, Green PHR, Katz MS. Endocrine complications of celiac disease:a case report and review of the literature[J]. Endocr Res, 2019, 44:27-45.